Drugmakers have been criticized for cost-sharing assistance programs that encourage patients to use brand-name drugs instead of cheaper, generic alternatives. The federal government has frowned on the help, but there are expensive medicines for cancer and rheumatoid arthritis that don't have generic equivalents.